Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 19Neutropenia 13Hodgkin Disease 5Lymphoma 4Lymphoma, Large B-Cell, Diffuse 3Chemotherapy-induced Neutropenia 3Triple Negative Breast Neoplasms 2Febrile Neutropenia 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Recurrent Uterine Corpus Carcinoma 1Rectal Neoplasms 1Neurofibrosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1Fever 1Endometrial Adenocarcinoma 1

Interventions

Fluorouracil 72Leucovorin 71Oxaliplatin 47Irinotecan 31Capecitabine 24Bevacizumab 23Folfox protocol 20Cetuximab 15Chemotherapy, Adjuvant 13Celecoxib 7Aspirin 6Laparoscopy 5XELOX 4Panitumumab 4Neoadjuvant Therapy 4Levamisole 4dehydroftorafur 3Tegafur 3Surgical Procedures, Operative 3Observation 3Floxuridine 3vatalanib 2tislelizumab 2pertuzumab 2encorafenib 2atezolizumab 2Trastuzumab 2Standard of Care 2Semaxinib 2Selenium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Colonic Neoplasms × pegfilgrastim × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡